Alphabet's forward P/E is historically low and 28.11% below Nasdaq's, making it an attractive buy at current levels. Click ...

Alphabet's AI integration, robust cash flow, and profitable Google Cloud make it a top investment choice. See more on GOOG ...

The London-based business – which launched in 2021 – will use the funds to further its research, expand its team and continue ...

Isomorphic Labs, the Alphabet Inc.-owned company that uses artificial intelligence to discover drugs, has raised $600 million ...

We recently published a list of Tariff Hits and More: 10 AI Stocks in the Spotlight. In this article, we are going to take a look at where Alphabet Inc. (NASDAQ:GOOG) stands against other AI ...

Isomorphic Labs, an Alphabet-backed AI biotech firm, raised $600M to boost its AI drug design engine, expand clinical ...

Like many tech stocks, Alphabet's (NASDAQ: GOOGL) (NASDAQ: GOOG) stock pulled back in recent months. Investors still question its position in the artificial intelligence (AI) landscape ...

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital for the first time. The $600 ...

AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding within Google parent company Alphabet, raising $600 million to advance its ...